Table 2 |
||||||||||||
|
Chronogram of the study |
||||||||||||
| Informed Consent |
□ |
|||||||||||
|
|
||||||||||||
| Randomization |
□ |
|||||||||||
|
|
||||||||||||
| Exams/Visits |
After Injection |
|||||||||||
|
|
||||||||||||
| Baseline |
pos-reperfusion |
3rd–5th day of reperfusion |
5th to 7th day |
Up to 1 h |
12 h |
24 h |
6th to 9th day |
1 month |
3 months |
6 months |
1 year |
|
|
|
||||||||||||
| Medical visit |
□ |
□ |
□ |
□ |
□ |
□ |
||||||
| ALT, AST, AP, PT, aPTT and INR |
□ |
|||||||||||
| Total Cholesterol, LDL-cholesterol, HDL-cholesterol and Triglycerides |
□ |
|||||||||||
| Full blood panel, Glucose, Urea, Creatinine, Na+, K+, CRP |
□ |
□ |
□ |
□ |
||||||||
| CK-MB mass, Troponin I |
□ |
□ |
□ |
□ |
□ |
|||||||
| Electrocardiogram |
□ |
□ |
□ |
□ |
□ |
□ |
□ |
□ |
□ |
□ |
||
| Echocardiogram |
□ |
□ |
□ |
□ |
□ |
|||||||
| Cardiac MRI |
□ |
□ |
||||||||||
| Coronary angiography |
□ |
□ |
||||||||||
| Cells transplant |
□ |
|||||||||||
| Cells sample storage |
□ |
|||||||||||
| SF-36, Minnesota and Seattle QOL |
□ |
□ |
□ |
□ |
||||||||
| QALY Evaluation |
□ |
□ |
□ |
|||||||||
|
ALT and AST: alanine and aspartate aminotransferases, respectively; AP: alkaline phosphatase; INR: international normatized ratio; PT: prothrombin time; aPTT: activated partial thromboplastin time; CRP: C-reactive protein; MRI: magnetic resonance image; QOL: quality of life questionnaires; QALY: quality adjusted life year. | ||||||||||||
Dohmann et al. Trials 2008 9:41 doi:10.1186/1745-6215-9-41 |
||||||||||||
